Trial Profile
An investigator sponsored trial assessing Tagraxofusp in combination with other drugs in patients with Acute myeloid leukemia (AML)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 06 Aug 2019
Price :
$35
*
At a glance
- Drugs Tagraxofusp (Primary) ; Antineoplastics
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 06 Aug 2019 New trial record
- 02 Aug 2019 According to a Stemline Therapeutics media release, this trial is expected to start in 4Q19/1H20.